HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Appropriators' Interest Could Point To FDA Supplement Programs Funding Boost

This article was originally published in The Rose Sheet

Executive Summary

House appropriators' letter to FDA Commissioner Gottlieb suggests they are listening to dietary supplement industry concerns and may be considering a funding boost for the Office of Dietary Supplement Programs, says executive Mike Greene.

You may also be interested in...



Supplement GMP Inspections Slowing As FDA Makes 'Potential' Data Useful

FDA doesn't expect o continue increasing GMP inspections at the rate established from fiscal 2013 through 2017, says Cara Welch, assistant director of the office in the agency's Office of Dietary Supplement Programs."We're not going to keep growing at that rate because we have a lot of regulations we have to inspect and we're always resource strapped," she said at a recent industry conference.

Making Nutritionals Eligible For Health Savings Accounts Whets Congress' Appetite

The supplement Industry and members of Congress open a line of communication on including dietary supplements into FSA/HSA spending programs, says CRN President Steve Mister.

Supplement Industry Oversight Among FDA Programs Targeted For $86M Budget Cut

The first budget proposal by President Trump suggests research by FDA's National Center for Toxicological Research on food- and nutritional supplement-related issues will be curtailed as part of a $3m cut to the center's appropriation.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121375

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel